제약
Cornell study links GLP-1 drugs like Ozempic and Wegovy to lower household food spending
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
Households that start GLP-1 appetite-suppressing medications such as Ozempic and Wegovy reduce food spending within months, including at grocery stores and limited-service restaurants, according to new research from Cornell University based on linked survey responses and transaction data.
Researchers from Australia have reported positive results from a Phase II clinical trial of a new carbohydrate-based drug for treating sepsis. The trial, involving 180 patients in China, demonstrated the drug's ability to reduce the condition's severity. This development offers hope for the first targeted therapy against a leading cause of global deaths.
AI에 의해 보고됨
A Delhi High Court verdict on January 12 has allowed Indian pharma company Zydus Lifesciences to manufacture and sell a biosimilar version of Bristol Myers-Squibb's cancer drug Nivolumab. This ruling could pave the way for more affordable immunotherapy treatments for cancer patients in India. Nivolumab is effective against various cancers, with its patent set to expire in May 2026.
Egypt's Minister of Health and Population, Khaled Abdel Ghaffar, held an expanded meeting on Monday with representatives of relevant state bodies to discuss ways to support pharmaceutical manufacturers and draft a comprehensive policy framework for boosting local production and localizing biopharmaceutical and biological products.
AI에 의해 보고됨
다이이치산쿄가 2월 2일부터 응급피임약 노르베로의 비처방 판매를 시작한다고 발표했다. 이는 일본에서 처방전 없이 이러한 알약을 구입할 수 있는 첫 사례다. 안전을 위해 훈련받은 약사 감독 하에 복용해야 한다.
Chile's Public Health Institute warned of two new risks linked to leuprorelina-containing drugs, used for advanced prostate cancer treatment. These include liver issues like fatty liver and severe skin reactions that can be fatal. The review drew from international evidence, with no local cases reported in the past 12 years.
AI에 의해 보고됨
The RD Saúde group, owner of the Raia and Drogasil chains, obtained a license to produce and sell over 20 molecules of over-the-counter medicines starting in 2026. The initiative was announced during the RD Day in São Paulo. The products will be launched under the Bwell brand.
Egypt and Kazakhstan discuss pharmaceutical technology transfer and health cooperation
2026년 01월 13일 06시 14분SciNeuro와 노바티스, 17억 달러 알츠하이머 약물 계약 체결
2026년 01월 12일 01시 52분India and Egypt strengthen pharmaceutical ties through high-level delegation visit
2026년 01월 10일 18시 59분Egypt backs African Medicines Agency, pushes for continent-wide regulatory integration
2026년 01월 09일 09시 41분FNE measures in celecoxib market generate over US$ 346 million in savings
2025년 12월 18일 19시 32분타케다 AI 개발 건선 알약 시험 성공
2025년 12월 13일 06시 15분Public enterprises ministry prioritises support for pharmaceutical affiliates: El-Shimy
2025년 12월 12일 12시 54분알츠하이머 약물 시험, 암의 다중 표적 접근법 채택
2025년 12월 10일 17시 32분Egypt and Belarus discuss expanded health cooperation and joint production
2025년 12월 07일 13시 42분Oral β2-agonist targeting muscle metabolism shows promise for type 2 diabetes and obesity